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Previous studies suggested that the cross talk between NK cells and other cell types is 
crucial for the regulation of both innate and adaptive immune responses. In the present 
study, we analyzed the phenotypic and functional outcome of the interaction between 
resting or cytokine-activated NK cells and eosinophils derived from non-atopic donors. 
Our results provide the first evidence that a natural cytotoxicity receptor (NCR)/NCR 
ligand-dependent cross talk between NK  cells and eosinophils may be important to 
upregulate the activation state and the effector function of cytokine-primed NK cells. 
This interaction also promotes the NK-mediated editing process of dendritic cells that 
influence the process of Th1 polarization. In turn, this cross talk also resulted in eosino-
phil activation and acquisition of the characteristic features of antigen-presenting cells. 
At higher NK/eosinophil ratios, cytokine-primed NK cells were found to kill eosinophils 
via NKp46 and NKp30, thus suggesting a potential immunoregulatory role for NK cells in 
dampening inflammatory responses involving eosinophils.
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inTrODUcTiOn
NK cell function is to a large extent regulated by activating and inhibitory cell surface receptors. 
A number of triggering receptors responsible for NK cell activation have been identified and molecu-
larly characterized during the last decade. For example, NKp46, NKp30, and NKp44 (collectively 
termed natural cytotoxicity receptors, NCRs) are mostly expressed by NK cells and represent crucial 
receptors for the recognition and killing of most target cells (1–3). In recent years, two NKp30 ligands 
were identified, including the HLA-B associated transcript 3 protein (BAG6) and B7-H6 (4–6), but 
the identity of the endogenous cell surface ligands for NKp46 receptor remains mostly unknown (7). 
Other activating receptors involved in target cell recognition and lysis are represented by NKG2D, 
DNAM-1, 2B4, and NTBA (3). In contrast to NCRs, the cellular ligands for these receptors have been 
identified. NKG2D recognizes stress-induced ligands such as MICA/MICB and ULBPs, whereas 
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DNAM-1 recognizes poliovirus receptor (PVR, CD155) and 
Nectin-2 (CD112); 2B4 recognizes CD48, while NTBA mediates 
homotypic interactions (8).
Human NK cells also express inhibitory receptors, compris-
ing a variety of HLA class-I-specific ones that include killer cell 
immunoglobulin-like receptors and the CD94/NKG2A heter-
odimer (9–12), which, upon interactions with self-HLA class-I 
molecules, prevent NK cell-mediated attack of autologous healthy 
cells. On the other hand, cells in which HLA class-I expression 
is downregulated (for example, following tumor transformation 
or viral infection) become susceptible to NK-mediated killing.
In addition to their important role in the control of viral 
infections and malignancies, recent studies indicate that NK cells 
can efficiently participate to the shaping of adaptive immune 
responses (13–16). In this context, it has been shown that acti-
vated NK  cells, by a mechanism termed “dendritic cells (DCs) 
editing,” may contribute to the quality control of DCs undergoing 
maturation by exerting a selection of the fittest DCs for optimal 
antigen presentation (17–19). Accumulating evidence suggests 
that the NK cell influence on the adaptive immune response is 
also tuned by other innate immune cells that are localized at the 
site of infection or in the tumor microenvironment (20, 21). These 
cells further modulate the ability of NK cells to regulate DC edit-
ing and maturation, either by releasing type I or type II cytokines 
or by directly interacting with NK cells (22). Thus, the effect of 
the interaction between NK and DCs may be conditioned by the 
characteristics of the inflammatory microenvironment in which 
immune responses occur (17, 23). Moreover, NK cells may deliver 
important signals contributing to T cell polarization toward type 
1 (Th1) immune responses directly in secondary lymphoid com-
partments (SLCs) (13, 17, 24–26).
Eosinophils are an end-stage type of granulocyte derived 
from primordial stem cells in the bone marrow that is known to 
circulate through the peripheral bloodstream and tissues. After 
trafficking to tissues, eosinophils bind to specific sites because of 
an extracellular matrix protein, fibronectin.
Subsequently, eosinophils receive signals to degranulate 
and release the preformed components of their granules, such 
as major basic protein, eosinophil cationic protein, eosinophil-
derived neurotoxin, and eosinophil peroxidase. These proteins 
target any foreign antigen, promote inflammation to the area, and 
may cause significant damage to surrounding structures (27, 28).
Moreover, eosinophils by releasing several type I and type 
II cytokines, growth factors, and chemokines can display both 
pro-inflammatory and anti-inflammatory activities (27, 28). 
Eosinophils express receptors for many of these soluble factors 
(that promote longevity of eosinophils in tissues), as well as innate 
receptors including pattern recognition receptors such as toll-like 
receptors (TLR 1–5, 7, 9) (29).
In addition, it was proposed that eosinophils may process and 
present a variety of microbial, viral, and parasitic antigens and, 
following activation, express high levels of HLA class-II and co-
stimulatory molecules, and upregulate CD62L. For these reasons, 
eosinophils may rapidly traffic to regional lymph nodes, where 
they can function as antigen-presenting cells (APCs) promoting 
CD4+ T cell proliferation and polarization (30–35). Importantly, 
eosinophils are observed in the peritumoral infiltrate of several 
types of cancers (27, 36), and the presence of tumor-associated 
eosinophilia seems to correlate with a better tumor prognosis (37).
Here, we show that, following coculture and direct cell-to-cell 
contact with eosinophils, NK cells upregulate their effector func-
tion. This process is dependent on the engagement of NKp46 and 
NKp30 triggering receptors. The increase of NK  cell-mediated 
IFNγ production and cytotoxic activity against tumor cells 
results in an increased ability of NK cells to perform an efficient 
editing of DCs. In addition, we show that eosinophils acquire 
an activated phenotype, by the de novo expression of CD69, 
ICAM-1, and HLA class-II molecules. Moreover, the upregula-
tion of CD62L confers to eosinophils a migratory capacity to SLC 
of cells and the acquisition of features of APCs. Interestingly, at 
higher NK/eosinophil ratios, cytokine-primed NK  cells exert 
cytotoxic activity toward eosinophils through the engagement of 
NKp46 and NKp30, thus exerting a possible control on eosino-




The following mAbs produced in our laboratory were used in this 
study: anti-HLA class-I (A6/136, IgM), anti-2B4 (CO54, IgM), 
anti-NTBA (MA127, IgM), anti-CD48 (CO202, IgM), anti-CD9 
(M1B16 IgM), anti-DNAM-1 (F5, IgM), anti-NKp30 (F252, IgM), 
anti-NKp46 (KL247, IgM), anti-KIR3DL1/L2-S1 (AZ158, IgG2a), 
anti-KIR2DL2/L3 (GL183, IgG1), anti-KIR2DL1/S1 (11PB6 
IgG1), anti-NKG2A (Z199, IgG2b), anti-p75 (QA79, IgG1), 
anti-IRp60 (E59/126, IgG1), anti-LFA-1 (ECM17/120, IgM), 
anti-LFA-3 (TS2/9, IgG1), anti-CD16 (c127, IgG1), anti-HLA-
DR (D1.12, IgG2A), anti-PVR (M5A10, IgG1), anti-Nectin-2 
(L14, IgG2a), anti-MIC-A (BAM195, IgG1), anti-ICAM-1 (7E22, 
IgG1), anti-CD69 (c227, IgG1), anti-CD25 (MAR93, IgG1), 
anti-NKp44 (Z231, IgG1), anti-CD86 (FM95, IgG1), anti-CD1a 
(FM184, IgM).
The following commercial mAbs were also used: anti-CD62L 
(clone DREG-56, IgG1) mAb, anti-CCR3 (clone 61828, IgG2A) 
mAb, PE-conjugated IgG2A-specific goat anti-rat secondary rea-
gents (BD Biosciences, San Jose, CA, USA); anti-CXCR1 (IgG1) 
(Santa Cruz, CA, USA); anti-CCR4 (IgG1) (BD Pharmingen); 
anti-CXCR4 (IgG2b) (R&D); anti-ICAM2 (clone B-T1), anti-
ICAM3 (clone BR1) (Diaclone); anti-CD32 (IgG2a) (Beckman 
Coulter); anti-ULBP1 (clone M295), anti-ULBP2 (clone M310) 
and anti-ULBP3 (clone M550) (Amgen Inc., Seattle, WA, USA). 
Anti-PD-L1 and anti-PD-L2 (IgG1) were kindly provided by 
Prof. Daniel Olive (Aix Marseille Université, France).
Annexin V-FITC was purchased from Bender MedSystems 
(Vienna, Austria, Europe). ToPro3 Iodide was purchased from 
Invitrogen (Eugene, OR, USA). Cytofluorimetric analysis of 
eosinophlis was performed by gating on Annexin V−/ToPro3− 
cells. Anti-B7-H6 (IgG1) was kindly provided by Prof. Eric 
Vivier (Centre d’Immunologie de Marseille-Luminy, France). 
Anti-human IFNγ was purchased from R&D Systems Inc. 
(Minneapolis, MN, USA). Cytofluorimetric analysis was assessed 
by flow cytometry FACSCalibur; Becton Dickinson & Co. 
(Mountain View, CA, USA).
3
Pesce et al. NK/Eosinophil Cross Talk in Humans
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 510
isolation and culture of human 
leukocytes
Buffy coats from healthy donors were obtained from the 
Immunohematology and Transfusion Center at the S. Martino 
Hospital (Genova, Italy).
Approval was obtained by the ethical committee of IRCCS S. 
Martino-IST (39/2012) of Genova (Italy). Informed consent was 
provided according to the Declaration of Helsinki.
Buffy coats were mixed at ratio 1:1 with 2% Dextran T500 
(Pharmacosmos, Holbaek, Denmark). After sedimentation of red 
blood cells, the upper phase was separated into granulocytes and 
mononuclear cells by density gradient centrifugation. Residual 
erythrocytes in the pellet were gently lysed in water to yield a 
pure population of granulocytes. To obtain a pure population of 
eosinophils from granulocytes, we used the eosinophil isolation 
Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according 
to the manufacturer’s instruction. The purity of eosinophils was 
greater than 98% (defined as CD16−/2B4+/NTBA+ granulocytes, 
as shown in Figure S1 in Supplementary Material).
Notably, healthy donors were selected based on the percentage 
of eosinophils in peripheral blood and on their phenotype after 
separation. In particular, we discarded donors with a percentage 
of eosinophils more than 4% and with a phenotype indicating, 
according to the information found in the literature, a possible 
activation or sensitization of eosinophils (e.g., expression of CD69).
Purified eosinophils were resuspended in RPMI 1640 medium 
supplemented with 2 mM glutamine, 50 µg/ml penicillin, 50 µg/ml 
streptomycin, and 10% heat-inactivated FCS (Sigma-Aldrich, 
Taufkirchen, Germany), in the absence or in the presence of 
cytokines (IFNγ 500 U/ml, TNFα 200 U/ml, IL12 1 ng/ml, IL15 
20  ng/ml, GM-CSF 50  ng/ml, or IL5 50  ng/ml, all purchased 
from Peprotech Inc., London, UK) or in the presence of NK cells. 
Importantly, in all cytofluorimetric analyses, we only considered 
live eosinophils (Annexin V− and ToPro3− cells).
Myeloid DC were generated from monocytes purified using 
CD14 MicroBeads human Isolation Kit (Miltenyi Biotec) from 
PBMC of healthy donors. Monocytes were cultured in RPMI 
1640 containing 10% FCS, in the presence of IL4 and granulo-
cyte/macrophage colony-stimulating factor (GM-CSF) (Pepro 
Tech, London, UK) at final concentrations of 20 and 50 ng/ml, 
respectively. After 6 days of culture, cells were characterized by 
the CD14−CD1a+CD83− phenotype corresponding to immature 
DCs (iDCs). To generate CD83+CD86+ mature DCs, iDCs were 
stimulated overnight (o.n.) with LPS (Sigma-Aldrich) at a final 
concentration of 1 µg/ml.
Pure populations of NK cells were obtained from PBMC or 
lymphocytes using the NK  cell isolation kit (Miltenyi Biotec, 
Bergisch Gladbach, Germany) according to the manufacturer’s 
instruction. In some experiments, MACS CD15 micro beads 
were added to further improve depletion of granulocytes. The 
purity of NK  cells was greater than 98% NK  cells (defined as 
CD56+/CD3−).
Such freshly purified NK  cells were resuspended in RPMI 
1640 medium, supplemented with 2  mM glutamine, 50  µg/ml 
penicillin, 50 µg/ml streptomycin, and 10% heat-inactivated FCS 
(Sigma-Aldrich, Taufkirchen, Germany), in the presence of either 
1 ng/ml of IL12 (purchased from Peprotech Inc., London, UK) or 
20 ng/ml of IL15 (purchased from Peprotech Inc., London, UK). 
These pro-inflammatory cytokines were selected for their known 
activating properties on NK cells, and because, unlike IFNγ and 
GM-CSF, they do not affect eosinophil survival nor eosinophil 
phenotype (Figure S2 in Supplementary Material) (38–40).
Cells were plated at 105  cells/ml in round-bottom 96-well 
tissue culture plates (Costar, Corning Corp.). After overnight 
culture (o.n.), NK  cells were washed and incubated o.n. with 
purified eosinophils. Then, NK cells were harvested and assessed 
for surface phenotype, cytolytic activity and cytokine produc-
tion. For cytofluorimetric analyses, NK  cells and eosinophils 
were first identified on the basis of their size difference (FSC) 
and granularity (SSC) and then of different surface markers. In 
particular, NK cells were identified as CD56+/CD3− cells, whereas 
eosinophils were identified as CD16−/2B4+ granulocytes. Dead 
cells were defined as Annexin V+/ToPro3+ cells, thus, cytofluori-
metric analysis of eosinophlis was always performed by gating on 
Annexin V−/ToPro3− cells.
In some experiments, the same NK  cells, after exposure to 
eosinophils, were cocultured o.n. with iDCs. Then, DCs were har-
vested and maturation markers were assessed by flow cytometry. 
This analysis was performed by gating on CD1a+/ToPro3− cells.
For transwell (TW) experiments, NK  cells and eosinophils 
were placed in 24-well TW (0.3 µm pore size; Corning Costar), 
upper and bottom chamber, respectively. To obtain activated pol-
yclonally expanded NK cells (bulk), freshly isolated NK cells were 
cultured on irradiated feeder cells in the presence of 100 U/mL 
recombinant human IL2 (Proleukin; Chiron) and 1.5  ng/ml 
phytohemagglutinin (PHA) (GIBCO Ltd.).
Production of soluble receptors and 
immunofluorescence
Plasmids utilized for expression of human NKp30-Fc*, 
NKp46-Fc*, and DNAM-1-Fc* recombinant molecules were pre-
pared as previously described (41–43), utilizing pRB1-2B4Fcmut 
vector (kindly provided by M. Falco, Istituto G. Gaslini, Genova, 
Italy) that contains a mutagenized sequence coding for a human 
IgG1 portion that does not bind to Fc receptors. Soluble recep-
tors were produced in HEK293T  cell line (human embryonic 
fibroblast) and purified by affinity chromatography using Protein 
A-Sepharose 4 Fast Flow (Amersham Biosciences) (41–43). 
Eosinophils (1 × 105 cells) were incubated with 2 µg of NKp30-Fc* 
and NKp46-Fc* soluble receptors for 30  min at 4°C, washed 
and stained with PE-conjugated F(ab′)2 goat anti-human IgG 
(Jackson ImmunoResearch Laboratories) for 30 min at 4°C. Flow 
cytometry was performed using a FACSCalibur flow cytometer 
(BD Biosciences) and cells were analyzed with CellQuest Pro 
software (BD Biosciences).
rT-Pcr analysis
Total cellular RNA was extracted from eosinophils and from 
HEK293T  cell line (human embryonic fibroblasts) using an 
RNAeasy Micro Kit (Qiagen, Hilden, Germany). Oligo (dT)-
primed cDNA was prepared by standard technique using 
Transcriptor (Roche, Monza, Italy). Amplification of B7-H6 
cDNA (nt. 247-708, Accession N° NR_026750) was performed 
with Platinum Taq (Life Technologies Paisley, UK) for 35 cycles 
FigUre 1 | analysis of nK cell receptor ligands on eosinophils (eOs) freshly purified from healthy non-atopic donors. (a) EOs were analyzed for the cell 
surface expression of NK cell receptor ligands including ULBP1,2,3, MIC-A, CD48, CD58, and PVR. A representative donor out of 15 is shown (upper line). The 
expression of Nectin-2 and, as control, the staining with DNAM-1-Fc* soluble molecule are shown for two representative donors out of 20 analyzed (lower line). 
Open profiles indicate staining with the corresponding PE-conjugated anti-mouse or anti-human secondary reagents. (B) EOs were analyzed for the cell surface 
binding of NKp30-Fc* and NKp46-Fc* soluble molecules. Open profiles indicate staining with PE-conjugated anti-human IgG secondary reagent. A representative 
donor out of six is shown. (c) B7-H6 mRNA expression was assessed by RT-PCR in EOs and in HEK293T cell line. PCR products were run on a 0.8% agarose gel 
and visualized by ethidium bromide staining. RT-PCR was also performed with primers specific for CD63 and β-actin as positive controls.
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(30 s at 95°C, 30 s at 58°C, and 1 min at 68°C) using the follow-
ing primers: H6 for 2 5′ TGCTGTGGGCGCTGACGA and H6 
rev2 5′ GGTAGAACCCACTTGACTCA. β-actin and CD63 
amplifications were performed for 30 cycles using the same 
conditions and served as internal controls; primers used were: 
β-actin up 5′ ACTCCATCATGAAGTGTGACG; β-actin dw 5′  
CATACTCCTGCTTGCTGATCC; CD63 up 5′ CAGCCATGG 
CGGTGGAAG and CD63 dw 5′ CCACTCCCCCAGATGAGG. 
PCR products were run on a 0.8% agarose gel and visualized by 
ethidium bromide staining (16, 44).
cytolytic activity
NK cells that had been exposed to IL12 or IL15 and then cocultured 
with eosinophils were tested for cytolytic activity against various 
NK  cell-susceptible target cells, including K562 and allogeneic 
iDCs, in a classical 4-h 51Cr-release assay as previously described 
(22). In other experiments, the cytolytic activity of resting or 
cytokines-primed NK cells was evaluated against autologous or 
allogeneic freshly isolated eosinophils in a 4-h 51Cr-release assay 
(22). The concentration of mAbs used for masking experiments 
was 10 µg/ml. The E/T ratios are indicated in the figure legends.
cytokine Production
ELISA kits were used for measuring IFNγ assessment in the super-
natants of NK cells stimulated with eosinophils (BioSource Int. Inc., 
CA, USA). Ab-mediated blocking experiments were performed 
adding saturating amounts of purified anti-NKp46, anti-NKp30, 
anti-2B4, and anti-LFA1 mAbs at the onset of the cell cultures.
statistical analysis
Independent samples t-test was employed for evaluating quan-
titative variables. The test is a statistical technique that is used 
to analyze the mean comparison of two independent groups. 
The statistical level of significance was preset at 0.05. Graphic 
representation and statistical analyses were performed using the 
PASW Statistic version 18.0 software (formerly SPSS Statistics) 
(IBM, Italy) and GraphPad Prism 6 (GraphPad Software, La Jolla, 
CA, USA).
resUlTs
eosinophils express ligands for nK cell 
receptors
In agreement with previous studies, we found that eosinophils 
from non-atopic healthy donors express 2B4, NTBA, and IRp60 
receptors (45–47), while they do not express CD16 (Figure S1A in 
Supplementary Material) (48) and CD69 (49). Moreover, eosino-
phils expressed different chemokine receptors, including CD62L 
as well as CCR3 (50) and the ligands for the programmed cell 
death protein 1 (PD-L1 and PD-L2) (Figure S1B in Supplementary 
Material). To assess the possibility that NK cells and eosinophils 
may interact with each other, we analyzed the phenotype of 
resting eosinophils also for the surface expression of specific 
ligands for NK cell receptors. As shown in Figure 1A, eosinophils 
did not express ligands for NKG2D (MICA, ULBPs) or for the 
DNAM-1 receptor (PVR and Nectin-2), although some varia-
tions in Nectin-2 expression could be observed among different 
donors. On the other hand, eosinophils expressed the ligands for 
the activating coreceptors 2B4 (CD48), CD2 (CD58), and NTBA 
(NTBA itself) (Figure 1A; Figure S1B in Supplementary Material) 
(43). Regarding the LFA-1 ligands, freshly isolated eosinophils 
expressed ICAM-3, whereas they were negative for ICAM-1 
and ICAM-2 adhesion molecules (Figure S1B in Supplementary 
Material).
In order to assess the expression of NCR ligands on eosino-
phils, we used soluble NKp46-Fc* and NKp30-Fc* molecules. As 
shown in Figure  1B, both molecules react, albeit weakly, with 
eosinophils, thus indicating that these cells may express one or 
more ligands for NKp46 and NKp30.
FigUre 2 | analysis of cD69 surface expression on il12-conditioned nK cells after coculture with eosinophils (eOs) freshly purified from healthy 
non-atopic donors. (a) Resting NK cells or IL12-conditioned NK cells were cultured o.n. with either autologous (AUTO) or allogeneic (ALLO) EOs and then tested 
for CD69 expression. The NK/EOs ratio in the coculture was of 1 to 1. Surface expression of CD69 on NK cells was analyzed by gating on CD56+/CD3− cells. The 
percentage and median value of CD69+ NK cells are shown for one representative donor out of 10 analyzed. (B) IL12-conditioned NK cells were cocultured with 
allogeneic EOs, either in the presence of cell-to-cell contact (left) or in transwell (right). After o.n. incubation, NK cells were harvested and analyzed for CD69 
expression. Gray bars represent CD69 expression on NK cells cultured alone; black bars refer to CD69 expression on NK cells cocultured with EOs. The NK/EOs 
ratio in the coculture was of 1:1. The average of six independent experiments is shown (% ±SD). *P < 0.05. (c) IL12-conditioned NK cells were cocultured with EOs 
in the absence or in the presence of the indicated blocking mAbs; after o.n., NK cells were harvested and analyzed for CD69 expression. Gray bar represents CD69 
expression on NK cells cultured alone, black bar refers to CD69 expression on NK cells cocultured with EOs, ribbed bars represent CD69 expression on NK cells 
cocultured with EOs in the presence of the indicated blocking mAbs. NK/EOs ratio in the coculture was of 1:1. The average of six independent experiments is 
shown (% ±SD). *P < 0.05.
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In order to find out whether the NKp30 ligand expressed on 
eosinophils is the B7-H6 molecule [whose expression has been 
recently described on neutrophils/monocytes under inflamma-
tory conditions (51)], we used specific anti-B7-H6 mAbs and 
performed the analysis at the mRNA level by RT-PCR. These 
experiments indicate that fresh eosinophils, similar to iDCs, do 
not express B7-H6 mRNA nor surface B7-H6 protein (Figure 1C 
and not shown), thus suggesting the existence of alternative (addi-
tional) NKp30 ligand/s on these cells. Unfortunately, we could 
not evaluate the expression of BAG6, due to the unavailability of 
specific reagents. Collectively, these data demonstrate that eosino-
phils express several ligands for NK receptors, suggesting that the 
two innate cell types may interact and influence each other.
nK cells Upregulate cD69 expression  
and Their antitumor cytotoxicity after 
Direct contact with eosinophils
We next analyzed whether eosinophils could modulate the 
NK cell phenotype and effector function. In these experiments, 
NK  cells, either resting or short-term primed with IL12 or 
IL15, were cocultured o.n. with fresh autologous or allogeneic 
eosinophils. After o.n. coculture, NK cells were assessed for the 
expression of the early activation marker CD69. As shown in 
Figure  2A, the surface density and the percentage of CD69+ 
NK  cells were strongly upregulated on IL12-conditioned 
NK  cells, but not on resting NK  cells, in the presence of 
FigUre 3 | anti-tumor cytolytic activity of nK cells cocultured with 
fresh eosinophils (eOs). (a) Resting NK cells (left) or IL12-conditioned 
NK cells (right) were cultured o.n. with EOs at an E:T ratio of 1:1; then 
harvested and analyzed for cytolytic activity against K562 at various E:T 
ratios. Gray bars refer to lysis by NK cells cultured alone, black bars 
represent lysis by NK cells cocultured with EOs. The average of six 
independent experiments is shown (% ±SD). *P < 0.05. (B) IL12-conditioned 
NK cells were cocultured with EOs, either in the presence of cell-to-cell 
contact (top) or in transwell (bottom). After o.n. culture, NK cells were 
harvested and analyzed for cytolytic activity against K562 at E:T ratio of 10:1. 
Gray bars refer to lysis by NK cells cultured alone, black bars represent lysis 
by NK cells cocultured with EOs. The average of six independent 
experiments is shown (% ±SD). *P < 0.05.
6
Pesce et al. NK/Eosinophil Cross Talk in Humans
Frontiers in Immunology | www.frontiersin.org April 2017 | Volume 8 | Article 510
autologous or allogeneic eosinophils. The same results were 
obtained after stimulation of NK cells with IL15 (not shown). 
Importantly, CD69 upregulation was mainly detected following 
cell-to-cell contact, although a slight increase of CD69 expres-
sion was detectable also when NK cells and eosinophils were 
separated by a TW membrane (Figure 2B). In order to identify 
molecules that may be involved in the interaction between 
NK  cells and eosinophils, cocultures were performed in the 
presence of mAbs specific for different NK receptors, includ-
ing the adhesion molecule LFA-1 and the activating receptors 
NKp46, NKp30, 2B4, and DNAM-1. As shown in Figure 2C, 
the eosinophil-induced upregulation of CD69 on NK  cells 
was reduced by the combined antibody-dependent blockade 
of NKp46, NKp30, and LFA-1, but not by masking individual 
receptors (Figure 2C).
Regarding the expression of other classical activation mark-
ers (CD25 and NKp44), no major differences between IL12-
conditioned NK  cells and IL12-conditioned NK  cells in the 
presence of eosinophils could be detected, although these mol-
ecules were weakly increased in NK cells that had been cultured 
with eosinophils (data not shown).
The level of surface expression of the other molecules analyzed 
in these experiments (including NKG2D and 2B4) remained 
substantially similar in NK cells cultured either in the absence or 
in the presence of eosinophils (data not shown).
In the same set of experiments, NK cells were used as effector 
cells in cytolytic assays against K562 (a classical NK-susceptible 
tumor target). As shown in Figure 3A, IL12-stimulated NK cells 
displayed significantly increase of cytotoxicity after coculture 
with eosinophils (right). In contrast, under the same culture 
conditions, resting NK  cells did not acquire a higher cytolytic 
activity against the same target cells (left).
Notably, the stimulatory effect on NK  cell cytotoxicity was 
dependent on cell-to-cell contact, as no increase in cytotoxic 
activity was observed in TW experiments (Figure 3B).
nK cells release high amounts of iFnγ 
after Direct contact with eosinophils
In order to determine whether eosinophils could also promote 
the production of pro-inflammatory cytokines by NK  cells, 
coculture supernatants were evaluated for the presence of IFNγ 
(Figure  4). In these experiments, eosinophils did not induce 
IFNγ production by resting NK  cells. However, high amounts 
of this cytokine was detected in NK cells pre-activated o.n. with 
IL12. In line with the results above, there was no detectable IFNγ 
production by NK cells in the absence of NK/eosinophil direct 
contact (Figure 4A). In all these experiments, resting NK cells 
that had been exposed o.n. to IL12 plus IL18 were used as positive 
control.
In experiments aimed at defining the molecular interactions 
involved in the eosinophil-NK cells cross talk, cocultures were 
performed in the presence of mAbs specific for different NK 
receptors. As shown in Figure 4B, antibody-mediated masking 
of NKp46 and even more when used in combination with anti-
LFA-1 mAb inhibited IFNγ release by NK cells. Remarkably, the 
maximal effect of inhibition occurred again upon simultaneously 
masking of NKp46, LFA-1, and NKp30 (Figure 4B). By contrast, 
masking of other receptors (e.g., 2B4) had no substantial effect 
(Figure 4B and not shown).
Thus, both TW and masking experiments pointed to a critical 
role for receptor/ligand interactions during the NK/eosinophil 
cross talk, resulting in amplification of NK cell activation, as 
determined by the upregulation of CD69 expression and by the 
increases of cytotoxic activity and IFNγ production.
nK cells exposed to eosinophils  
acquire a higher capacity to Kill Myeloid 
iDcs and to induce Their Maturation
Next, we investigated whether coculture with eosinophils could 
promote NK cell-mediated killing of iDCs. In agreement with 
previous data, exogenous IL12-conditioned NK cells were able to 
kill iDCs (22); however, this activity was significantly increased 
after coculture with eosinophils, as shown in Figure 5A.
Next, we evaluated whether the interaction with eosino-
phils could influence the NK  cell capability of promoting 
FigUre 4 | analysis of iFn-γ secretion by nK cells after coculture with eosinophils (eOs). (a) Resting NK cells (CTR) or IL12-conditioned NK cells were 
cultured o.n. with EOs, either in the presence of cell-to-cell contact or in transwell. After o.n. culture, supernatants were harvested and then analyzed by ELISA for 
the presence of IFNγ. NK cells that had been exposed o.n. to IL12 plus IL18 were used for comparison. The NK/EOs ratio in the coculture was of 1:1. Average of six 
independent experiments is shown (pg/ml ± SD). **P < 0.01; ***P < 0.001. (B) IL12-conditioned NK cells were cocultured with EOs in the absence or in the 
presence of the indicated blocking mAbs; after o.n. culture, supernatants were harvested and then analyzed by ELISA for the presence of IFNγ. The NK/EOs ratio in 
the coculture was of 1:1. Average of six independent experiments is shown (pg/ml ± SD). *P < 0.05; **P < 0.01.
FigUre 5 | nK cells exposed to eosinophils (eOs) display a higher capability to kill myeloid immature Dcs (iDcs) and to induce their maturation.  
(a) IL12-conditioned NK cells were cultured o.n. with EOs at an E:T ratio of 1:1, then harvested and analyzed for cytolytic activity against iDCs at various E/T ratios. 
Gray bars refer to lysis by NK cells cultured alone, black bars represent lysis by NK cells cocultured with EOs. The average of six independent experiments is shown 
(% ±SD). *P < 0.05. (B) IL12-conditioned NK cells were cultured o.n. with EOs at an E:T ratio of 1:1; the same NK cells were then cocultured with iDCs. After o.n., 
dendritic cells (DCs) were harvested and assessed by flow cytometric analysis for maturation markers such as CD86, HLA-I, and HLA-DR. For comparison, iDCs 
were cultured either alone or with EOs and NK cells separately. These analyzes were performed by gating on CD1a+/ToPro3− cells. Open profiles indicate staining 
with PE-conjugated anti-mouse IgG secondary reagent. The percentage of CD86 and the median value of HLA-I and HLA-DR on DCs are shown for a 
representative donor out of six analyzed.
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DC maturation. To this end, IL12-conditioned NK  cells and 
eosinophils were cocultured o.n., then harvested, washed, 
and cultured with iDCs. After 24 h, the expression of CD86, 
HLA class-I and HLA class-II (i.e., HLA-DR) molecules on 
DCs was determined by cytofluorimetric analysis. As shown 
in Figure  5B, substantial increments in the mean expression 
of HLA molecules (both class I and II) and in the percent-
age of CD86-expressing cells were detected when iDCs were 
cocultured with NK cells plus eosinophils, as compared to iDCs 
cocultured with NK or eosinophils alone. In some experiments, 
eosinophils were removed before culturing NK cells with iDCs 
and also under these conditions DCs could undergo matura-
tion (not shown).
nK cells activate eosinophils to acquire 
Both Migratory Potential and the 
Phenotypic Features of aPcs
Next, we investigated whether phenotypic changes in eosinophils 
occurred following interaction with NK cells. To this end, fresh 
FigUre 6 | analysis of eosinophil (eO) activation induced by il12-conditioned nK cells. (a) EOs were cultured alone (CTR) or with IL12-conditioned 
NK cells at an E:T ratio of 1:1 in the presence or in the absence of neutralizing anti-IFNγ mAbs. After o.n. culture, EOs were harvested and assessed by flow 
cytometric analysis for maturation markers such as CD69, ICAM-1, CD62L, HLA-DR, and HLA-I. Surface expression of these markers on EOs was analyzed by 
gating on Annexin V−/ToPro3− cells. The percentage of viable EOs (Annexin V−/ToPro3−) was 30–55% in CTR, 70–85% in cocultures containing NK + IL12 and 
60–71% in those containing NK + IL12 + anti-IFNγ. The bars indicate the percentage of positive cells and the median value of HLA-I+ EOs. Gray bars refer to EOs 
cultured alone, black bars represent EOs cocultured with NK + IL12 cells and striped bars refer to EOs cocultured with NK + IL12 cells in the presence of 
neutralizing anti-IFNγ mAb. The average of six independent experiments is shown (% ±SD). *P < 0.05; ***P < 0.001. (B) Surface expression of the markers analyzed 
in panel (a) is shown for one representative donor out of 6 analyzed. Open profile indicates staining with PE-conjugated anti-mouse IgG secondary reagent. The 
percentage of CD69, ICAM-1, CD62L, HLA-DR, and the median value of HLA-I are indicated. (c) EOs cells were cultured with IL12-conditioned NK cells at an E:T 
ratio of 1:1 in the presence (+) or in the absence (−) of the indicated blocking mAbs; after o.n. culture, EOs were harvested and assessed by flow cytometric analysis 
for CD69 expression by gating on AnnexinV−/ToPro3− cells. Open profiles indicate staining with PE-conjugated anti-mouse IgG secondary reagent. The percentage 
of CD69 is shown for one representative donor out of six analyzed.
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eosinophils were cocultured with NK  cells (either resting or 
conditioned with IL12/IL15). At the end of the culture period, 
eosinophils were harvested and analyzed for the expression of a 
number of informative markers, including CD69, ICAM-1, HLA 
molecules, and CD62L. A significant de novo surface expres-
sion of CD69, ICAM-1, and HLA-DR molecules and a marked 
upregulation of HLA class-I and CD62L molecules was detected 
on eosinophils cocultured with IL12-conditioned NK  cells 
(Figures 6A,B). The same results were obtained by pre-treating 
NK cells with IL15. Resting NK cells did not induce any substan-
tial effect (not shown).
Experiments were also performed in the presence of blocking 
anti-IFNγ mAbs to understand whether the de novo expression/
upregulation of the above surface molecules could be induced by 
IFNγ. As shown in Figures 6A,B, when cells were cultured in the 
presence of anti-IFNγ mAbs, the expression of most of the above 
markers was reduced but not abolished (Figure 6B).
This indicates that the modification of eosinophil phenotype 
induced by cytokine-treated NK cells is in part, but not exclu-
sively, due to the production of IFNγ during coculture. Next, we 
determined if the same receptor/ligand interactions responsible 
for eosinophil-mediated induction of NK cell effector functions 
were also involved in the events leading to eosinophil activation. 
To this end, neutralizing mAbs specific for NKp46, NKp30, or 
LFA-1 were added, alone or in combination, to cocultures and 
the expression of CD69 on eosinophils analyzed. As shown in 
Figure 6C, mAbs, added individually, did not (or only modestly) 
inhibit CD69 expression. In contrast, CD69 expression was sig-
nificantly decreased in eosinophils when the neutralizing mAbs 
specific for NK receptors were used in combination. Particularly 
strong inhibition was obtained when anti-NKp46, anti-NKp30, 
and anti-LFA-1 mAbs were simultaneously added to the coculture.
nK cells are capable of Killing Both 
autologous and allogeneic  
eosinophils via nKp46 and nKp30
To investigate whether eosinophils could represent possible 
targets for NK cell cytotoxicity, fresh (not-activated) allogeneic 
eosinophils were exposed either to resting or to IL2-activated 
NK cells (bulk) in 51Cr-release cytolytic experiments. As shown 
in Figure 7A, IL2-activated, but not resting NK cells, displayed 
a strong cytotoxic activity toward allogeneic eosinophils. In 
order to evaluate the contribution of one or another activating 
FigUre 7 | cytolytic activity of il2-conditioned or resting nK cells 
against eosinophils (eOs) freshly purified from healthy non-atopic 
donors. (a) IL2-conditioned (bulk) or resting NK cells were tested in 
51Cr-release assay against EOs at various E:T ratios. Black bars represent 
lysis by bulk NK cells; gray bars refer to lysis by resting NK cells. The average 
of six independent experiments is shown (% ±SD). (B) IL2-conditioned 
NK cells (bulk) were analyzed for their cytolytic activity against EOs in the 
absence or in the presence of the indicated blocking mAbs at various E:T 
ratios. Black circles: E:T ratio of 20:1; gray squares: E:T ratio of 10:1; white 
circles: E:T ratio of 5:1. The average of six independent experiments is shown 
(% ±SD). *P < 0.05; **P < 0.01.
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NK receptor, cytolytic assays were performed in the presence of 
mAbs specific for major activating NK receptors. As shown in 
Figure 7B, NKp46 and NKp30 mainly contributed to the killing 
of eosinophils, since mAb-mediated masking of these receptors, 
resulted in significant inhibition of lysis, while mAbs directed to 
other activating NK receptors had no substantial effect.
Similar results were obtained in cytolytic assays performed in 
an autologous setting using IL12- or IL15- short-term-primed 
NK cells as effector cells. As shown in Figure 8A, both types of 
cytokine-activated NK cells displayed similar levels of cytotoxicity 
against autologous or allogeneic eosinophils, while NK cells pre-
cultured with IL4 or IL18 did not display any cytotoxicity against 
eosinophils (data not shown) (22). Notably, mAb-mediated 
disruption of inhibitory receptors/HLA class-I interactions did 
not result in increases of cytotoxicity (Figure 8A, left). These data 
suggest that HLA class-I molecules do not provide substantial 
protection to eosinophils from NK  cell-mediated cytotoxicity. 
In agreement with these results, eosinophils displayed a low 
expression of surface HLA class-I molecules as compared to other 
innate cells known to interact with NK cells (Figure 8B).
DiscUssiOn
In the present study, we have analyzed the cross talk occurring 
between human NK  cells and eosinophils. We show that, after 
direct contact with eosinophils, cytokine-primed NK  cells 
become significantly activated, acquiring the capability of releas-
ing high amounts of IFNγ, killing tumor cells more efficiently, and 
promoting adaptive immune responses, by killing unfit iDC and 
favoring the selection of appropriate mDCs. All of these functional 
activities appear to be primarily consequent to the interaction 
between NCRs, expressed on NK  cells, and surface ligands on 
eosinophils cell surface. In turn, primed NK cells could strongly 
influence eosinophils by inducing an APC-like phenotype. In 
addition, we show that, at high NK/eosinophil ratios, NK cells can 
efficiently kill both autologous and allogeneic eosinophils, sug-
gesting the existence of NK cell-mediated mechanisms capable of 
exerting a regulatory control on eosinophil activity.
At the site of infection, activation of immune cells results in 
the secretion of pro-inflammatory cytokines and chemokines, 
resulting in the recruitment of different immune cells. Recruited 
NK cells receive activating signals inducing their effector func-
tions and participate to the functional interactions with other 
immune cells (15, 17, 21, 22, 52).
Previous studies suggested an important role for the interac-
tion between NK cells and monocyte-derived DCs in both the 
initiation of the immune response and induction of down-stream 
adaptive T cell immunity (13, 17, 52–55). For example, activated 
NK cells acquire the capability of killing iDCs (via the NKp30 
activating receptor), which do not express adequate amounts of 
HLA molecules (55). By this mechanism, referred to as “NK cell-
mediated editing of DCs,” NK cells may ensure the quality of DCs 
undergoing maturation. In addition, through the production of 
soluble factors (such as IFNγ and TNFα) released upon activation, 
NK cells favor the progression of DC maturation (56). Thus, the 
final outcome of the “DC editing process” would be the selection 
of the “fittest” DCs, thanks to the removal of those that, due to the 
low expression of HLA molecules, would fail to mediate efficient 
antigen presentation and T-cell priming (18, 22, 57).
As previously shown, additional cell types, including mac-
rophages and neutrophils, that are either resident in tissues or 
recruited to inflammatory sites, may interact each other and 
generate a cross talk with NK  cells during the early phases of 
innate immune responses (16, 21, 22, 41, 58, 59). Thanks to 
the demonstration that eosinophils interact functionally with 
NK  cells, the present study extends the number of innate cells 
participating in cross talks among cells of the innate immunity. 
We show that after direct interaction with eosinophils, NK cells 
undergo activation, release IFNγ, and upregulate the cytotoxic 
activity against different targets. The eosinophil-induced pheno-
typic and functional effects on NK  cells were to a large extent 
dependent on close cell-to-cell interaction involving activating 
NK receptors, including NKp30 and NKp46. Moreover, in agree-
ment with studies on the cross talk between NK and other innate 
cells, we show that eosinophils can also improve the ability of 
NK cells to induce DC editing and maturation.
Only few studies have addressed the interaction between 
NK cells and eosinophils; for example, it has been reported that 
NK cells may exhibit a chemoattraction toward the eosinophil-
released IL8 and that this effect is increased by IL15 (60). Moreover, 
in allergic rhinitis, NK cells were shown to infiltrate the epithelial 
layers and the stroma of nasal tissue in response to CX3CL1 and 
CCL26. In asthmatic patients, a positive correlation was docu-
mented between the eosinophil and NK  cell numbers and the 
status of cell activation (61). In addition, two recent studies have 
suggested that NK  cells may promote apoptosis of eosinophils 
(49, 62), but the molecular mechanisms underlying these events 
FigUre 8 | cytolytic activity of short-term-conditioned nK cells against autologous (aUTO) or allogeneic (allO) eosinophils (eO). (a) NK cells were 
cultured o.n. with or without IL12 or IL15 and then tested in 51Cr-release assay against autologous (upper panel) or allogeneic (lower panel) EOs. The cytolytic activity 
was tested in the absence or in the presence of the indicated blocking mAbs at an E:T ratio of 10:1. White bars refer to lysis by resting NK cells, black bars 
represent lysis by IL12-conditioned NK cells, gray bars refer to lysis by IL15-conditioned NK cells. The average of eight independent experiments is shown (% ±SD). 
*P < 0.05; **P < 0.01; ***P < 0.001. P value was obtained by comparing the conditions NK + IL12 (black bars) or NK + IL15 (gray bars) in the presence of the 
different mAbs with the same conditions in the absence of mAbs (CTR). (B) Different leukocyte populations derived from peripheral blood of healthy donors were 
analyzed for surface expression of HLA-I and HLA-E molecules (median values are indicated). A representative donor out of 15 is shown.
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were not addressed. Our study is shedding light on some of these 
molecular mechanisms and provides evidence that the NK cell 
cytotoxicity against eosinophils is dependent on NKp46, NKp30, 
and LFA-1 engagement (Figure 8). In accordance with these data, 
we found that eosinophils are capable of binding soluble forms of 
the NKp30 and NKp46 receptors. Interestingly, the NKp30-Fc* 
binding did not reflect the expression of the recently identified 
NKp30-ligand, B7-H6, suggesting that eosinophils similar to 
monocyte-derived DCs (5) express a different cell surface ligand 
for NKp30.
After coculture with NK cells, eosinophils de novo expressed 
CD69 (an activation marker), and ICAM-1 (important for cellu-
lar adhesion), and upregulated CD62L (a receptor involved in the 
recruitment of eosinophils to the SLCs) and HLA class-I and -II 
molecules (that confer the capability to present antigens). These 
events were mainly dependent on cell-to-cell contact, although 
also IFNγ released by NK cells substantially contributed to this 
effect, as demonstrated by the partial inhibition detectable in the 
presence of blocking anti-IFNγ mAb (63). Regarding the expres-
sion of CD69, our data are in line with those recently reported by 
Awad et al. (49), although the culture conditions used by these 
authors were different. In this context, it is possible that these 
conditions [i.e., coculture of cells in a Th2 environment (IL-5)] 
may be responsible for some additional differences in the out-
come of the cross talk between NK and eosinophils, including the 
role of activating NK receptors in the process of recognition and 
killing of eosinophils.
In the past, eosinophils have been merely considered end-
stage cells involved in host protection against parasite infection 
(64); however, recent studies have changed this perspective and 
eosinophils are now considered multifunctional leukocytes 
involved in tissues homeostasis, in innate immune responses 
to certain pathogens, and in modulation of adaptive immune 
responses (65–68). In addition, several lines of evidence suggest 
that eosinophils are capable of producing immunoregulatory 
cytokines and are actively involved in modulation of T  cell 
responses (66). Remarkably, a role for eosinophils as APCs 
has recently been proposed (69). In this context, tradition-
ally, eosinophils have been associated with Th2-responses 
(66, 70–72), in line with their ability to function as APCs and to 
release Th2-cytokines (28). However, it is important to underline 
that the majority of these results were obtained with eosinophils 
derived from atopic or cancer patients. Actually, it is now well 
established that eosinophils respond to Th1-cytokines, such as 
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IFNγ (63, 73, 74), and their active role in Th1-responses has been 
proposed (75, 76). In line with this concept, our data suggest that 
eosinophils derived from healthy donors are capable of driving 
activated NK cells toward an inflammatory response leading to an 
effective “editing” of DCs, resulting in induction of Th1 (and not 
Th2) responses. Our data also suggest that NK cells can activate 
eosinophils to express or upregulate CD69, ICAM-1, CD62L, and 
HLA molecules, which may favor their migration toward SLCs, 
where they can present antigens to T cells (66).
In conclusion, our study provides novel information on 
the molecular mechanisms involved in the cross talk between 
eosinophils and NK cells, demonstrating that these interactions 
are mediated mainly by NCR/NCR ligand interactions. Our 
results also show that, upon engagement of these receptors, 
NK  cells that had been exposed to innate cytokines, amplify 
their effector function against tumor cells and DCs. These 
innate cytokines are primarily released by other players of 
innate immune responses recruited at the same inflammatory 
sites. In addition, NK  cells upon encountering eosinophils 
may either release IFNγ and promote their maturation toward 
an APC-like migratory cell or, on the contrary, may kill them 
terminating their activity and contributing to dampening an 
excessive inflammatory response (Figure 9).
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FigUre s1 | Phenotypic analysis of eosinophils (eOs) freshly separated 
from healthy non-atopic donors. (a) EOs were purified from peripheral blood 
of healthy non-atopic donors. The purity of EOs was confirmed by analyzing the 
phenotype of cells obtained after separation. In particular, EOs expressed 
omogeneously the phenotype CD16−/2B4+/NTBA+ (left panel), while neutrophils 
expressed omogeneously the phenotype CD16+/2B4−/NTBA− (right panel). Dead 
cells were defined as Annexin V+/ToPro3+ cells, thus cytofluorimetric analysis of 
EOs was always performed by gating on Annexin V−/ToPro3− cells. (B) EOs were 
assessed by flow cytometric analysis for a number of surface molecules by 
gating on AnnexinV−/ToPro3− cells. The phenotypic analysis of neutrophils was 
used for comparison. The data shown in the table were obtained from the 
analysis of 20 different healthy donors.
FigUre s2 | analysis of survival and activation of eosinophils (eOs) 
purified from healthy non-atopic donors after culture in the presence of 
selected cytokines. (a) EOs were cultured in the absence or in the presence 
of cytokines (IL5, GM-CSF, IFNγ, TNFα, IL12, IL15), then harvested and 
assessed by flow cytometric analysis for survival markers such as Annexin V 
and ToPro3. The percentage of Annexin V−/ToPro3− EOs is indicated for one 
representative donor out of 30 analyzed. (B) EOs were cultured in the absence 
or in the presence of cytokines (IL5, GM-CSF, IFNγ, TNFα, IL12, IL15), then 
harvested and assessed by flow cytometric analysis for the expression of CD69 
surface molecules by gating on Annexin V−/ToPro3− cells. The bars indicate the 
percentage of CD69+ EOs. The average of 20 independent experiments is 
shown (% ±SD). *P < 0.05; **P < 0.01. P value was obtained by comparing the 
conditions in the presence of the different cytokines with the condition in the 
absence of cytokines (CTR).
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